AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25388643
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection hyaluronic acid (IAHA)
Trial: 25064093
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation programme (motor training and cognitive-behavioural therapy)
Trial: 17662095
Drug: All agents
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All agents (group 1, group 2, group 3)
Trial: 15787921
Drug: levobupivacaine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.2% (1 ml x kg(‐1))
Trial: 15787921
Drug: ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.2% (1 ml x kg(‐1))
Trial: 15787921
Drug: bupivacaine 0.2%
RxNorm normalized name: BUPivacaine 0.2%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.2% (1 ml x kg(‐1))
Trial: 11923128
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with sequential paclitaxel and doxorubicin-based combination chemotherapy
Trial: 3524419
Drug: Ceftazidime 4
RxNorm normalized name: CEFTAZIDIME 40ML/ML INJ,50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 4 g per day for 26 to 63 days (mean, 45 days)
Trial: 16229991
Drug: Sequential intravenous/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intravenous/oral moxifloxacin (400 mg once a day)
Trial: 16229991
Drug: Intravenous piperacillin-tazobactam
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous piperacillin-tazobactam (3.0/0.375 g every 6 h) followed by oral amoxicillin-clavulanate (800 mg every 12 h)
Trial: 16229991
Drug: Intravenous piperacillin-tazobactam
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate
Trial: 8522666
Drug: Urinastatin (100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinastatin (100,000 U dose immediately after arrival, followed by three 100,000 U doses at 8-hour intervals within the first 24 hours)
Trial: 22706336
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% once daily (1 drop PM)
Trial: 22706336
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% twice daily (1 drop AM and PM)
Trial: 15476485
Drug: Anti-CD25 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD25 monoclonal antibody (anti-CD25 mAb) administered to high immunological risk patients
Trial: 9766411
Drug: Nebulized furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized furosemide 1 mg/kg
Trial: 9766411
Drug: Nebulized furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized furosemide 2 mg/kg
Trial: 337094
Drug: Continue antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue antibiotics (CCG + chloramphenicol or clindamycin)
Trial: 337094
Drug: Stop antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop antibiotics
Trial: 26324740
Drug: lenvatinib 24
RxNorm normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenvatinib 24 mg orally per day (n = 261)
Trial: 26324740
Drug: lenvatinib 24
RxNorm normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenvatinib 24 mg orally per day
Trial: 21860340
Drug: Buprenorphine (BUP)
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine (BUP) sublingual tablet (14-20 mg)
Trial: 19626663
Drug: INGAP peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INGAP peptide 600 mg/day
Trial: 19626663
Drug: INGAP peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INGAP peptide 300 mg/day
Trial: 17377106
Drug: Ketamine (intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (intraoperative 0.3 mg/kg and postoperative infusion at 0.1 mg x kg(‐1) x h(‐1))
Trial: 10434906
Drug: PSA level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA level over 20 ng ml‐1
Trial: 10434906
Drug: PSA level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA level below 20 ng ml‐1 and Gleason score below 6
Trial: 21478817
Drug: CNI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI therapy
Trial: 19252046
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy for 12 weekly sessions followed by two monthly booster sessions
Trial: 16988200
Drug: 100-mg 2-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg 2-hour intravenous infusion
Trial: 16988200
Drug: 200-mg oral
RxNorm normalized name: lesinurad
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200-mg oral administration twice daily
Trial: 16988200
Drug: 200-mg/d continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg/d continuous intravenous infusion
Trial: 15163481
Drug: Trivalent, intranasal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent, intranasal, live attenuated influenza virus vaccine
Trial: 10912948
Drug: Gemcitabine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (200 mg/m2, with possible escalation to 250 mg/m2), administered as a 360 min infusion on days 1, 8, and 15 of a 28-day cycle.
Trial: 9487432
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (corticosteroid)
Trial: 30650322
Drug: Tafenoquine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine (300 mg single dose)
Trial: 30650322
Drug: Primaquine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (15 mg once daily for 14 days)
Trial: 24523332
Drug: Recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant erythropoietin (Eprex) administered hypodermically 10,000 units 3 times a week during 6 months
Trial: 9821025
Drug: Intravenous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous low molecular weight heparin (LMWH)
Trial: 9821025
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (LMWH)
Trial: 8605054
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (AP; 300 mg monthly)
Trial: 8605054
Drug: Cotrimoxazole (CTX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (CTX; 160 mg trimethoprim and 800 mg sulfamethoxazole every other day)
Trial: 8605054
Drug: Dapsone-pyrimethamine (DP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone-pyrimethamine (DP; 100 mg weekly dapsone and 25 mg biweekly pyrimethamine)
Trial: 2529731
Drug: Meperidine (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (0.35 mg/kg)
Trial: 2529731
Drug: Morphine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.04 mg/kg)
Trial: 21813328
Drug: Food supplementation
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplementation rich in arginine (peanuts, equivalent to 1 g of arginine/day)
Trial: 19380449
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg/day) plus Letrozole (2.5 mg/day)
Trial: 19380449
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Letrozole (2.5 mg/day)
Trial: 17050503
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lisinopril plus 50 mg losartan
Trial: 3534629
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg b.i.d. for 4 weeks
Trial: 27399197
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg bd
Trial: 20964867
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with daily 1-hydroxycholecalciferol (Alfacalcidol; 1 μg) and calcium supplement
Trial: 12584032
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/day; n = 20)
Trial: 12584032
Drug: Transdermal 17beta
RxNorm normalized name: 17beta oestradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta estradiol (50 microg/day; n = 39)
Trial: 9301412
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 14 g inulin added to a low-fat spread
Trial: 3521207
Drug: Low-dose streptokinase
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose streptokinase (SK) combined with low-dose heparin
Trial: 3521207
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Heparin and Low-dose SK)
Trial: 29797503
Drug: Fructose (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (any dose)
Trial: 29797503
Drug: Allulose (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allulose (5 g, 10 g, pooled doses)
Trial: 24438561
Drug: Light Force
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light Force (40 g)
Trial: 24438561
Drug: Heavy Force
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy Force (120 g)
Trial: 22394412
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment (group I)
Trial: 22394412
Drug: Diuretic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic and vasodilator treatment (group II)
Trial: 18243665
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of interferon-gamma (rIFN-gamma or nIFN-gamma) and narrowband UVB (NB-UVB)
Trial: 18243665
Drug: Narrowband UVB
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Narrowband UVB (NB-UVB) monotherapy
Trial: 12964857
Drug: HBO2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 therapy (5 sessions of breathing 95% oxygen at 2.5 atm abs for 100 min)
Trial: 8871872
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) therapy at a dose of 5 MU subcutaneously three times weekly for 6 months
Trial: 1518433
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous (SC) octreotide infusion
Trial: 1518433
Drug: Octreotide injection
RxNorm normalized name: octreotide Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide injection
Trial: 6378615
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 mg BID, dose increased biweekly)
Trial: 30950431
Drug: Anti-HCV antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-HCV antibody testing
Trial: 30950431
Drug: Adjusted odds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted odds of testing positive for anti-HCV antibody
Trial: 19606675
Drug: Melatonin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administration for 3 months in patients with functional dyspepsia and H. pylori infection (n=30)
Trial: 19606675
Drug: Melatonin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administration for 3 months in patients with functional dyspepsia without H. pylori infection (n=30)
Trial: 8869897
Drug: UV‐A1 irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV‐A1 irradiation (twice- and once-weekly)
Trial: 1740065
Drug: Outpatient bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outpatient bowel preparation
Trial: 1740065
Drug: Inpatient bowel
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient bowel preparation
Trial: 6655288
Drug: Dengue 2
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue 2 vaccine (0.5 ml, doses of 10(1.8)‐10(5.5) plaque-forming units)
Trial: 31185041
Drug: 0.12% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% betamethasone valerate ointment applied twice a day after washing or bathing by parents
Trial: 25569028
Drug: High-dose barium
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose barium impaction therapy
Trial: 19822100
Drug: Oral hyposensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hyposensitization therapy with low doses of nickel
Trial: 16421461
Drug: Amisulpride (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (400 mg/day up-titrated from 100 mg/day over 1 week)
Trial: 16791717
Drug: Pharmacotherapy follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy follow-up program
Trial: 1725028
Drug: Ramipril (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5, 5, or 10 mg once daily)
Trial: 1725028
Drug: Enalapril (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5, 10, or 20 mg once daily)
Trial: 27266883
Drug: Kinesio Taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio Taping added to physical therapy (exercise and manual therapy)
Trial: 20926996
Drug: Tasocitinib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasocitinib (15 mg or 30 mg twice daily)
Trial: 18414066
Drug: High salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High salt diet (3.86 g, 168 mmol/24 hours sodium)
Trial: 18414066
Drug: Low salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low salt diet (1.3 g, 56 mmol/24 hours sodium)
Trial: 12459399
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) daily
Trial: 1760824
Drug: Isosorbide-5-mononitrate (IS-5-MN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 2 x 40 mg/day
Trial: 1760824
Drug: Atenolol (AT)
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol (AT) 100 mg/day
Trial: 1760824
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of IS-5-MN and AT
Trial: 31767518
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg at Weeks 0, 2, 4, and 6, followed by placebo at Week 8, alirocumab at Week 10, placebo at Weeks 12 and 14.
Trial: 31767518
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg.
Trial: 31767518
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg and placebo.
Trial: 29130954
Drug: Tolvaptan (≤15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (≤15 mg/day)
Trial: 29130954
Drug: Increased furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased furosemide (≤40 mg/day)
Trial: 26401089
Drug: Moxifloxacin-based sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin-based sequential therapy (MBST)
Trial: 21928714
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream of Calendula officinalis extract
Trial: 19720909
Drug: Paclitaxel 135
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg/m(2) over 24 hours plus Cis 50 mg/m(2) day 2 every 3 weeks (PC)
Trial: 19720909
Drug: Vinorelbine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 30 mg/m(2) days 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (VC)
Trial: 19720909
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m(2) day 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (GC)
Trial: 19720909
Drug: Topotecan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 0.75 mg/m(2) days 1, 2, and 3 plus Cis 50 mg/m(2) day 1 every 3 weeks (TC)
Trial: 15364659
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group serving at other S-L sites
Trial: 11443156
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day pegvisomant
Trial: 8018795
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of GRF (1 micrograms/kg)
Trial: 23296629
Drug: soluble human
RxNorm normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soluble human triggering receptor expressed on myeloid cells-1 (sTREM-1)
Trial: 23296629
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PSP (>9 ng/ml) and PCT (>2 ng/ml)
Trial: 16289171
Drug: Physiological REM
RxNorm normalized name: REM-422
DrugBank: REM-422 (DB19304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological REM sleep augmentation via REM sleep rebound after selective REM sleep deprivation
Trial: 16289171
Drug: Pharmacological REM
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacological REM sleep augmentation by administering an acetylcholinesterase inhibitor
Trial: 12888122
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg fludrocortisone p.o.
Trial: 12888122
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg aldosterone i.v.
Trial: 8689991
Drug: Flumazenil (0.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.4, 0.8, and 1 mg bolus injections followed by 1 mg/h infusion for 3 hours)
Trial: 8689991
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 hours infusion)
Trial: 30551121
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g · kg‐1 BW NaHCO3
Trial: 30551121
Drug: 0.1 g
RxNorm normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g · kg‐1 BW NaHCO3
Trial: 30551121
Drug: Control (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.3 g · kg‐1 BW placebo)
Trial: 18033807
Drug: Mild ovarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild ovarian stimulation/GnRH antagonist co-treatment with single embryo transfer
Trial: 18033807
Drug: Standard stimulation/GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard stimulation/GnRH agonist long protocol with transfer of two embryos
Trial: 16372578
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 20 mg three times daily, orally
Trial: 16372578
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment plus TMZ
Trial: 12523089
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education (two two-hour group sessions followed by one or two individual sessions administered by a nurse and a physiotherapist)
Trial: 9607046
Drug: Triviraten Berna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triviraten Berna Vaccine